MediSpend, a global technology company providing best-in-class solutions for the life sciences industry, has officially announced the acquisition of Real Life Sciences (RLS), which happens to be a leader in advanced anonymization solutions for clinical trial and other data.
According to certain reports, the stated acquisition will effectively reinforce MediSpend’s commitment towards expanding its presence and capabilities in the Governance, Risk and Compliance (GRC) space.
More on the same would reveal how this particular deal will make it possible for the company to support life sciences and contract research organizations (CROs) in navigating complex regulatory requirements to disclose clinical trial results data, while simultaneously protecting participant privacy and intellectual property.
Here, RLS’s flagship platform i.e. RLS Protect will tread up a long distance to let organizations across the board disclose clinical trial data with health authorities, research partners, internal teams, and publications. Markedly enough, this they will be able to do without sacrificing participant privacy and commercially confidential information at any touchpoint.
“This combination is a transformative milestone in Real Life Sciences’ growth journey,” said Elliot Zimmerman, CEO of Real Life Sciences. “Becoming a MediSpend company empowers us to further enhance our solutions for life sciences organizations as they navigate an evolving set of global regulatory requirements for clinical transparency, data sharing and participant privacy. Together, we are uniquely positioned to deliver innovative solutions to clients across the life sciences industry.”
Taking a more specific view of all the offerings Real Life Sciences will bring into MediSpend’s ecosystem moving forward, we begin from RLS Protect – Anonymization. This one is basically an advanced quantitative risk modeling tool, which one can use to ensure participant privacy across shared clinical data and documents. In essence, RLS Protect arrives on the scene well-equipped to leverage proprietary natural language processing and accelerate the identification, as well as classification of personal data found within clinical data.
The next solution in line would be RLS Protect – Redaction. The stated technology packs together a set of different yet comprehensive tools that have their utility rooted in redacting data, including commercially confidential information from documents in compliance with global regulatory standards.
Another solution set to become a part of MediSpend’s technological base is Real Life Sciences’ Voluntary Data Sharing facility. For better understanding, we ought to mention how this facility allows for you to access streamlined sharing of anonymized clinical trial data internally and externally. Not just that, it also enables an accelerated brand of secondary research.
Rounding up highlights would be RLS’ Anonymization Services. You see, the company deploys an expert-driven team to deliver anonymization and redaction projects on time and per health authority guidance. To achieve the given objective, these experts would bank upon the RLS Protect’s proprietary technology and proven methodologies.
Among other things, it must be acknowledged that RLS’ solutions address compliance requirements across major regulatory bodies, including EMA (EU) 536/2014, EMA Clinical Data Publication Policy 0070, Health Canada Public Release of Clinical Information (PRCI), FDA disclosure mandates, and more.
“Real Life Sciences’ innovative solutions align perfectly with MediSpend’s mission to empower life sciences companies with technology that drives growth, compliance and transparency,” said Leigh Powell, Executive Chairman of MediSpend. “This acquisition expands the company’s reach into research and development (R&D) compliance and the protection of vital intellectual property as well as enhances our ability to serve a broader market and support our clients with tools to meet evolving global regulatory demands.”
